FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to pharmacological therapy, and can be used for treating mitochondrial DNA depletion syndrome (MDS), characterized by at least one mutation in the DGUOK gene. Therapeutically effective amount of a composition containing at least deoxyadenosine (dA) and deoxyguanosine (dG) is administered to a patient for this purpose.
EFFECT: method provides the effective treatment of MDS characterized by at least one mutation in the DGUOK gene by administering a composition containing dA and dG.
7 cl, 7 dwg, 5 ex
Title | Year | Author | Number |
---|---|---|---|
DEOXYNUCLEOSIDE THERAPY OF DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS, INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES | 2016 |
|
RU2721492C2 |
TREATMENT OF MITOCHONDRIAL DISEASES | 2016 |
|
RU2745611C2 |
USE OF THYMIDINE AND DEOXYCYTIDINE AS A COMBINED NUTRITIONAL PRODUCT FOR THE TREATMENT OF TK2-ASSOCIATED MITOCHONDRIAL MYOPATHY | 2023 |
|
RU2811282C1 |
METHOD OF CORRECTING FUNCTIONAL STATE OF TK2-ASSOCIATED MITOCHONDRIAL MYOPATHY | 2023 |
|
RU2811280C1 |
COMBINED THERAPEUTIC NUTRITIONAL PRODUCT FOR THERAPY OF TK2-ASSOCIATED MITOCHONDRIAL MYOPATHY | 2023 |
|
RU2811769C1 |
TREATMENT OF CYSTIC DISEASE DUE TO TNF-ALPHA | 1997 |
|
RU2186580C2 |
METHOD OF CORRECTION OF OXIDATIVE STRESS IN LEBER'S HEREDITARY OPTIC NEUROPATHY | 2019 |
|
RU2704013C1 |
METHOD FOR PREDICTION OF ACUTE MYOCARDIAL ISCHEMIA OUTCOME | 2016 |
|
RU2649774C1 |
METHOD FOR EXPERIMENTAL BIOTHERAPY OF B16/F10 MELANOMA | 2022 |
|
RU2779698C1 |
PEPTIDE FRAGMENTS OF BASIC PROTEIN MYELIN, PHARMACEUTICAL COMPOSITIONS BASED ON THEREOF AND APPLICATION OF THESE COMPOSITIONS FOR TREATMENT OF CEREBROSPINAL SCLEROSIS | 1998 |
|
RU2198893C2 |
Authors
Dates
2024-09-26—Published
2016-06-17—Filed